Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.

Gynecologic oncology - 1 Jul 2015

Seagle Brandon-Luke L, Yang Chia-Ping Huang, Eng Kevin H, Dandapani Monica, Odunsi-Akanji Oluwatosin, Goldberg Gary L, Odunsi Kunle, Horwitz Susan Band, Shahabi Shohreh

Abstract excerpt

OBJECTIVE: To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival outcomes, the effects of microtubule stabilizers on human ovarian carcinoma cells (OCCs) expressing TP53 HSMs were studied in vitro. Survival outcomes of patients with high grade serous ep...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Cell Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genes, p53

Share to Neoplasms, Glandular and Epithelial

Share to Ovarian Neoplasms

Share to Paclitaxel

Share to Tubulin Modulators

Source

Open in PubMed Open full text

Identifiers

PMID: 25958320
DOI: 10.1016/j.ygyno.2015.04.039
PMCID: PMC5303002

Genes

BAX
HGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25958320-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.PMID 25958320Read ↗

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.Semantic proximity Read ↗

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancerSemantic proximity Read ↗

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP InhibitionSemantic proximity Read ↗

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

p53 protein aggregation promotes platinum resistance in ovarian cancer.Semantic proximity Read ↗

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.Semantic proximity Read ↗

Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian CancersSemantic proximity Read ↗

TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.Semantic proximity Read ↗

Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.Semantic proximity Read ↗

Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancerSemantic proximity Read ↗

Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian CancerSemantic proximity Read ↗

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.